Board of Directors
Dr. Bassil I. Dahiyat co-founded Xencor in 1997 to commercially leverage his and Dr. Stephen Mayo’s seminal work at Caltech on proteins and the development of Protein Design Automation™ technology. Under Dr. Dahiyat’s leadership, Xencor has applied PDA to develop a pipeline of proprietary protein and antibody drug candidates, both internally and in partnership with leading biotechnology and pharmaceutical companies. He drives the company’s fundraising efforts, and has secured more than $85 million in financing to date. Dr. Dahiyat also leads the company’s scientific programs and has been instrumental in growing the company’s broad intellectual property portfolio. He is an inventor on 60 patents and patent applications, including Xencor’s Protein Design Automation® platform, and a co-author of 18 scientific papers. In 2005, Dr. Dahiyat was recognized as a technology pioneer by the World Economic Forum. Additionally, Dr. Dahiyat was named one of 2003′s Top 100 Young Innovators by MIT’s Technology Review magazine for his work on protein design and its development for therapeutic applications and has received awards from the American Chemical Society, the Controlled Release Society and Caltech. Dr. Dahiyat holds a Ph.D. in chemistry from Caltech and B.S. and M.S.E. degrees in biomedical engineering from Johns Hopkins University.
Chairman of the Board
Dr. Carter was appointed Chairman of the Board of Xencor, Inc. in December 2009. In November 2009, he joined Immune Design Corp. where he serves as Executive Chairman of the Board. In addition to his duties at Immune Design, Dr. Carter serves as Chairman of the Board at the TB Alliance, and is a member of a number of other Boards, including Moksha8, QLT, Inc., and Dr. Reddy’s Lab. Prior to joining Immune Design, Dr. Carter was a member of the management team at ZymoGenetics, Inc. where he held various positions, including Chief Executive Officer from April 1998 to January 2009. Dr. Carter first joined ZymoGenetics in 1986 as Vice President of Research and Development. In 1988 Novo Nordisk A/S acquired ZymoGenetics and, in 1994, Dr. Carter was promoted to Corporate Executive Vice President and Chief Scientific Officer for Novo Nordisk. In 2000, Dr. Carter led the negotiations that established ZymoGenetics as an independent company from Novo Nordisk. As CEO, he was instrumental in transforming ZymoGenetics from the research arm of a European biopharmaceutical company to a company that developed and commercialized Recothrom®. Dr. Carter also held various positions of increasing responsibility at G.D. Searle & Co., Ltd. from 1982 to 1986 and was a Lecturer at Trinity College, University of Dublin from 1975 to 1982. He received a B.Sc. with Honors in Botany from the University of Nottingham, England, and a Ph.D. in Microbiology from Queen Elizabeth College, University of London.
Jonathan Fleming is the Managing Partner of Oxford Bioscience Partners, an international venture capital firm specializing in life science technology based investments, with offices in Boston, Massachusetts and Seoul, Korea. He is a General Partner of the Korea-Seoul Life Science Fund.
Mr. Fleming has been in the investment business for over twenty-seven years, starting and financing growth companies in the United States, Europe, Israel and Asia. Prior to joining OBP in 1996, he was a Founding General Partner of MVP Ventures in Boston, MA. He began his investment career with TVM Techno Venture Management in Munich, Germany. Mr. Fleming has also co-founded Medica Venture Partners, a venture capital investment firm specializing in early stage healthcare and biotechnology companies in Israel. Mr. Fleming is a director of several private companies including Dicerna Pharmaceuticals, Lab Partners, Radius Pharmaceuticals, Greenlight and Railrunner. He is also a director of Leerink Swann, a Boston based investment bank specializing in healthcare companies. In addition, Mr. Fleming is a Senior Lecturer at the MIT Sloan School of Business, a Lecturer at the Harvard Medical School, a Trustee of the Museum of Science in Boston, a Member of the Board of NEHI, a healthcare oriented think tank and policy advocacy group. Mr. Fleming is on the Scientific Advisory Board of the Massachusetts Life Science Center and is a member of the Chancellors Commercialization Advisory Board of the University of Texas System. Mr. Fleming holds a Master’s degree in Public Administration from Princeton University and a Bachelor of Arts degree from the University of California, Berkeley.
Dr. Foster has been involved in the biologics industry for nearly 25 years. He is currently Corporate Vice President leading a Seattle-based research site for Novo Nordisk focused on discovery and development of biologics for the treatment of chronic autoimmune diseases including RA, IBD and SLE. Prior to Novo Nordisk, Dr. Foster spent more than 22 years at ZymoGenetics where he was involved with research programs that delivered four products to the market. The products included an engineered tPA analog now licensed and marketed by Eisai as Cleactor; human activated Protein C now licensed and marketed by Eli Lilly as Xigris; human Factor VIIa marketed by Novo Nordisk as NovoSeven; and human Thrombin now marketed by ZymoGenetics as RecoThrom. The research programs under his guidance have also resulted in four new protein biologics that are currently in clinical development. Dr. Foster earned a Ph.D. at the University of Washington in the laboratory of Dr. Earl Davie. He has published more than 120 papers in the field and is an inventor on more than 40 issued patents.
Atul Saran assumed the role of Senior Vice President, Corporate Development and Ventures, in 2011. He has responsibility for MedImmune’s corporate development activities, primarily including worldwide biologics and vaccines strategic business development transactions for the AstraZeneca Group, as well as responsibility for new MedImmune corporate ventures and oversight of MedImmune Ventures.
Mr. Saran joined MedImmune in 2003 as the company’s first in-house corporate and securities lawyer and worked with the general counsel to develop a strategically focused legal department, in which he held positions of increasing seniority, most recently as vice president and deputy general counsel, with responsibility for managing the legal department (other than the intellectual property team). During his tenure in the legal department, Mr. Saran helped structure and complete critical initiatives and transactions for the organization, including the production of H1N1 vaccine for the U.S. government in 2009, the acquisition of MedImmune by AstraZeneca in 2007, the acquisition and divestiture of key pipeline technologies and various structured finance transactions. Mr. Saran also worked with the management team to establish the governance and operational framework for MedImmune Ventures and execution of its subsequent investment strategy. Mr. Saran came to MedImmune from Hogan & Hartson, where he was an associate attorney in the Private Equity/Emerging Business Practice Group.
Mr. Saran graduated summa cum laude from the University of Illinois College of Law, and received his bachelor’s degree in biological sciences from Stanford University. He also successfully completed two years of medical school at the University of Illinois College of Medicine and Step 1 of the United States Medical Licensing Examination.
Between 1996 and 2001, Mr. Stafford was a Managing Director of Stafford Trading, Inc., a business primarily involved in proprietary trading operations and venture capital investments. The company, headquartered in Chicago, operated a successful specialist and market making business and conducted proprietary trading in equities, futures and fixed income products. Mr. Stafford’s venture capital activities consisted of investments in over 40 companies, and he is a Board Member on several of these companies, including Clinical Micro Sensors, Inc., Xencor and All Optical Networks, Inc. At the end of 2001, the Company was purchased by TD Options, LLC and Mr. Stafford became Chief Executive Officer of Ronin Capital, LLC, a registered broker dealer with proprietary trading operations encompassing equity, fixed income and derivative securities. The Company is a Member of The Chicago Board Options Exchange, The Chicago Board of Trade, The Chicago Mercantile Exchange and other U.S. principal exchanges. Mr. Stafford attended The University of Chicago.
Mr. Stewart worked from 1975 to 1993 as a trader in the financial markets on the Chicago Board Options Exchange. In 1987, he co-founded Aware, Inc., a publicly traded intellectual property company in the DSL (digital subscriber line) telecommunications space and served as the company’s Chairman of the Board until 1999. The company had its IPO in 1996. Mr. Stewart has invested in a number of high-tech companies, including Genetics Institute in 1983. Mr. Stewart graduated from Yale University with a BA and from Northwestern University with an MBA.
Harold R. Werner is a co-founder and general partner of HealthCare Ventures, a venture capital fund specializing in the health care industry. Mr. Werner has served as a director of over 30 public and private companies. Prior to the formation of HealthCare Ventures in 1985, Mr. Werner was Director of New Ventures for Johnson & Johnson Development Corporation. Mr. Werner currently serves on the Board of Directors of TetraLogic Pharmaceuticals Corporation, DecImmune, Inc., Aciex, Inc., Promedior, Inc., Xencor, Inc., Stemgent, Inc., and InfaCare Pharmaceutical Corp. Mr. Werner received his B.S. and M.S. degrees from Princeton University and an M.B.A. from the Harvard Graduate School of Business Administration.